文献速递肝病消化道出血

在肝硬化患者中,胃静脉曲张封堵术加用卡维地洛并未降低胃静脉曲张出血复发率

Addition of Carvedilol to Gastric Variceal Obturation Does Not Decrease Recurrence of Gastric Variceal Bleeding in Patients With Cirrhosis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-02-14

这项多中心随机对照试验纳入121例肝硬化胃静脉曲张出血患者,比较重复胃静脉曲张封堵术(GVO)单用与联合卡维地洛的二级预防效果。结果显示,联合卡维地洛未降低胃静脉曲张出血复发率(23% vs 34%,P=.18),但降低了上消化道出血复发风险(RR 0.44,95%CI 0.24-0.80,P=.007),且不良事件更多(53% vs 15%,P<.001),两组平均生存时间无显著差异(P=.30)。

要点

  • 卡维地洛联合GVO未降低胃静脉曲张出血复发率(23% vs 34%,P=.18)。
  • 卡维地洛与上消化道出血复发风险降低相关(RR 0.44,95%CI 0.24-0.80,P=.007)。
  • 联合卡维地洛组不良事件发生率更高(53% vs 15%,P<.001),生存时间无显著差异。

核心结论

  • 在肝硬化患者中,胃静脉曲张封堵术加用卡维地洛未降低胃静脉曲张出血复发率,但与上消化道出血复发减少相关,且不良事件显著增多。
  • 两组平均生存时间无显著差异(21±18个月 vs 25±20个月,P=.30)。

研究设计与样本

  • 多中心随机对照试验,纳入121例肝硬化患者(年龄20-80岁),内镜下证实胃静脉曲张出血且在初始GVO后血流动力学稳定至少3天。
  • 患者随机分为重复GVO组(n=61)和重复GVO联合卡维地洛组(n=60)。

主要发现

  • 胃静脉曲张出血复发:重复GVO组21例(34%)vs 联合卡维地洛组14例(23%),P=.18。
  • 上消化道出血复发:重复GVO组29例(48%)vs 联合卡维地洛组17例(28%),P=.03;卡维地洛与上消化道出血复发风险降低相关(RR 0.44,95%CI 0.24-0.80,P=.007)。
  • 腹水(RR 2.69,95%CI 1.33-5.48,P=.006)和肝癌(RR 2.10,95%CI 1.03-4.28,P=.04)与胃静脉曲张出血复发相关。
  • 腹水(RR 3.02,95%CI 1.59-5.73,P=.001)和肝癌(RR 2.07,95%CI 1.10-3.88,P=.02)与上消化道出血复发相关。
  • 不良事件:联合卡维地洛组53% vs 重复GVO组15%,P<.001;平均生存时间21±18个月 vs 25±20个月,P=.30。

关键数值与推荐

  • 胃静脉曲张出血复发率:重复GVO组34% vs 联合卡维地洛组23%(P=.18)。
  • 上消化道出血复发率:重复GVO组48% vs 联合卡维地洛组28%(P=.03)。
  • 卡维地洛与上消化道出血复发风险的RR为0.44(95%CI 0.24-0.80,P=.007)。
  • 不良事件发生率:联合卡维地洛组53% vs 重复GVO组15%(P<.001)。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Gastric variceal bleeding (GVB) frequently recurs after hemostasis by gastric variceal obturation (GVO). We performed a multicenter, randomized controlled trial to determine the efficacy of carvedilol plus GVO in secondary prophylaxis of GVB. METHODS: We performed a prospective study of 121 patients with cirrhosis (ages 20-80 years) with GVB proven by endoscopy within 24 hours of bleeding and stable hemodynamics for at least 3 days after initial GVO. Patients were randomly assigned into a group that underwent repeated GVO (n = 61) or a group received repeated GVO plus carvedilol (n = 60). Recurrent GVB, upper gastrointestinal bleeding (UGIB), adverse events, and survival were compared between the groups. RESULTS: GVB recurred in 21 patients (34%) in the group that received repeated GVO and 14 patients (23%) in the group that received repeated GVO plus carvedilol (P = .18). Ascites (relative risk [RR], 2.69; 95% CI, 1.33-5.48; P = .006) and hepatoma (RR, 2.10; 95% CI, 1.03-4.28; P = .04) were associated with recurrent GVB. Twenty-nine patients (48%) in the group that received repeated GVO and 17 patients (28%) in the group that received repeated GVO plus carvedilol had recurrent UGIB (P = .03). Carvedilol (RR, 0.44; 95% CI, 0.24-0.80; P = .007) was associated with reduced risk of UGIB recurrence. Ascites (RR, 3.02; 95% CI, 1.59-5.73; P = .001) and hepatoma (RR, 2.07; 95% CI, 1.10-3.88; P = .02) were associated with recurrent UGIB. A higher proportion of patients in the group that received repeated GVO plus carvedilol (53%) had adverse events than the group that received repeated GVO (15%) (P < .001). Mean survival times were 21 ± 18 months in the group that received repeated GVO vs 25 ± 20 months in the group that received repeated GVO plus carvedilol (P = .30). CONCLUSION: In a randomized controlled trial, we found that addition of carvedilol to GVO did not decrease recurrence of GVB in patients with cirrhosis but was associated with decreased recurrence of UGIB. However, carvedilol plus GVO produced significantly more adverse events. Mean survival times did not differ significantly between groups. ClinicalTrials.gov no: NCT02504723.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Chen WC, Hsin IF, Chen PH, et al. Addition of Carvedilol to Gastric Variceal Obturation Does Not Decrease Recurrence of Gastric Variceal Bleeding in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2019. PMID: 30772583. doi:10.1016/j.cgh.2019.02.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。